Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
The identification of new targets to address unmet medical needs, better in a personalized way, is an urgent necessity. The introduction of PARP1 inhibitors into therapy, almost ten years ago, has represented a step forward this need being an innovate cancer treatment through a precision medicine ap...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI AG
2023-08-01
|
| Serier: | Molecules |
| Fag: | |
| Online adgang: | https://www.mdpi.com/1420-3049/28/15/5849 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
